share_log

SVB Leerink Downgrades Design Therapeutics to Market Perform, Announces $6 Price Target

Benzinga ·  Aug 15, 2023 20:18

SVB Leerink analyst Joseph Schwartz downgrades Design Therapeutics (NASDAQ:DSGN) from Outperform to Market Perform and announces $6 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment